on The Vanguard Group, Inc. (isin : US12572Q1058)
Vanguard's Disclosure on Avadel Pharmaceuticals Stake
The Vanguard Group, Inc. has released its Form 8.3 in accordance with the Irish Takeover Panel Act, detailing its interests in Avadel Pharmaceuticals plc. The disclosure, dated January 14, 2026, reflects Vanguard's holdings as of January 13, 2026. Vanguard holds a 6.03% stake, equating to 5,871,161 ordinary shares.
Recent transactions include the purchase of 703 shares and the sale of 1,078 shares, both at a price of 21.48 USD per unit. No cash-settled or stock-settled derivative transactions were reported. Furthermore, Vanguard reported no indemnity or option arrangements, nor any agreements regarding voting rights or future acquisitions related to these securities.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all The Vanguard Group, Inc. news